Results of a Phase II Study of Cladribine, Low Dose Cytarabine and Venetoclax, Alternating with Azacitidine and Venetoclax in Patients with Higher Risk Chronic Myelomonocytic Leukemia or Myelodysplastic Syndromes
Montalban-Bravo, Guillermo, Short, Nicholas J., Chien, Kelly S., Alvarado Valero, Yesid, Daver, Naval, Borthakur, Gautam, Swaminathan, Mahesh, Maiti, Abhishek, Hammond, Danielle E., Nogueras-Gonzalez, Graciela, Huang, Xuelin, Schneider, Heather, Shelly, Kristen, Kadia, Tapan M., Kantarjian, Hagop M., Garcia-Manero, Guillermo
Published in Blood (02.11.2023)
Published in Blood (02.11.2023)
Get full text
Journal Article